Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Sangamo Therapeutics, Inc. , a genomic medicine company, today announced that the American Society of Gene & Cell Therapy has accepted 20 Sangamo abstracts for presentation at the 27th ASGCT Annual...
Source: marketscreener.com